DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells
Abstract
Aim: To investigate the influence of DDX11-AS1 on paclitaxel (PTX) resistance in lung adenocarcinoma (LUAD). Methods: LncRNA expression and functional enrichment analyses were processed via bioinformatics methods. DDX11-AS1 expression was detected via quantitative real-time PCR. Cell counting kit-8, colony formation, flow cytometry and comet assays were manipulated to measure cell proliferation, apoptosis, cell cycle and DNA damage repair, respectively. Western blot was used to assess DNA damage-related protein expression. Results:DDX11-AS1 was in a high expression status in LUAD, and could promote LUAD cell proliferation and PTX resistance, while suppressing cell apoptosis. DNA damage repairing ability was also modulated by the change of DDX11-AS1 expression. Conclusion: LncRNA DDX11-AS1 promotes DNA damage repair to enhance PTX resistance in LUAD.
References
- 1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
- 2. . Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9(2), 117 (2018).
- 3. . Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma: tumor initiation and progression. Int. J. Mol. Sci. 19(4), 1259 (2018).
- 4. . Paclitaxel's mechanistic and clinical effects on breast cancer. Biomolecules 9(12), 789 ( 2019).
- 5. Weekly paclitaxel – an effective treatment for advanced breast cancer. Anticancer Res. 33(6), 2623–2627 (2013).
- 6. . Antimitotic drugs in the treatment of cancer. Cancer Chemother. Pharmacol. 76(6), 1101–1112 (2015).
- 7. . How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 25(18), 2677–2681 (2014).
- 8. Long non-coding RNAs: mechanism of action and functional utility. Noncoding RNA Res. 1(1), 43–50 (2016).
- 9. . The emerging role of lncRNAs in cancer. Nat. Med. 21(11), 1253–1261 (2015).
- 10. LncRNA DDX11-AS1 promotes bladder cancer occurrence via protecting LAMB3 from downregulation by sponging miR-2355-5p. Cancer Biother. Radiopharm. 35(5), 319–328 (2020).
- 11. . Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis. Artif. Cells Nanomed. Biotechnol. 48(1), 572–583 (2020).
- 12. . Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis. Eur. Rev. Med. Pharmacol. Sci. 23(13), 5714–5729 (2019).
- 13. . Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 514(4), 1051–1057 (2019).
- 14. . Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signalling. Clin. Exp. Pharmacol. Physiol. 47(9), 1622–1631 (2020).
- 15. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 24(6), 3049–3061 (2020).
- 16. The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition. Am. J. Cancer Res. 9(10), 2233–2248 (2019).
- 17. . Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression. Mol. Med. Rep. 25(4), 123 (2022).
- 18. . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1), 139–140 (2010).
- 19. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 10(7), 479 (2019).
- 20. . Circ_0011292 enhances paclitaxel resistance in non-small cell lung cancer by regulating miR-379-5p/TRIM65 axis. Cancer Biother. Radiopharm. 37(2), 84–95 (2022).
- 21. The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/AKT pathway. Front. Oncol. 11, 637298 (2021).
- 22. MiR-1587 regulates DNA damage repair and the radiosensitivity of CRC cells via targeting LIG4. Dose Response 18(2), 1559325820936906 (2020).
- 23. Noncanonical agonist PPARgamma ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc. Natl Acad. Sci. USA 115(3), 561–566 (2018).
- 24. . Immune resistance in lung adenocarcinoma. Cancers (Basel) 13(3), 384 (2021).
- 25. . Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma. Biomed. Pharmacother. 123, 109771 (2020).
- 26. Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5. Cancer Cell Int. 21(1), 179 (2021).
- 27. . LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway. Ann. Hepatol. 20, 100258 (2021).
- 28. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1/p53 axis. Cancer Lett. 520, 282–294 (2021).
- 29. . Long non-coding RNA DDX11-AS1 promotes esophageal carcinoma cell proliferation and migration through regulating the miR-514b-3p/RBX1 axis. Bioengineered 12(1), 3772–3786 (2021).
- 30. Long non-coding RNA DDX11-AS1 promotes the proliferation and migration of glioma cells by combining with HNRNPC. Mol. Ther. Nucleic Acids 28, 601–612 (2022).
- 31. . Long noncoding RNA PANDA positively regulates proliferation of osteosarcoma cells. Anticancer Res. 37(1), 81–85 (2017).
- 32. A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep. 16(11), 1520–1534 (2015).
- 33. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 32(21), 2833–2847 (2013).
- 34. . Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Eur. Rev. Med. Pharmacol. Sci. 24(18), 9465–9472 (2020).
- 35. . Mechanisms of DNA damage, repair, and mutagenesis. Environ. Mol. Mutagen. 58(5), 235–263 (2017).
- 36. . DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 36(5-6), 278–293 (2022).